Skip to main content

Table 2 Frequency of fractures among ADT users and nonusers

From: Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand

  Any fractures (N = 1538) Hip fractures (N = 338) Vertebral fractures (N = 273)
No ADT (n = 16,167) 524 (3.2 %) 120 (0.7 %) 136 (0.8 %)
Any ADT (n = 9377) 1014 (10.8 %) 218 (2.3 %) 137 (1.5 %)
  GnRH agonists + Anti-androgens 611 (60.3 %) 110 (50.5 %) 72 (52.6 %)
        GnRH agonist only 130 (12.8 %) 43 (19.7 %) 25 (18.2 %)
        Anti-androgen only 147 (14.5 %) 43 (19.7 %) 22 (16.0 %)
        Orchiectomy alone 38 (3.7 %) 10 (4.6 %) 9 (6.6 %)
 Orchiectomy + pharmacologic ADT 88 (8.7 %) 12 (5.5 %) 9 (6.6 %)
  1. ADT androgen deprivation therapy, GnRH gonadotropin-releasing hormone